References
- MorelloCMHirschJDLeeKCNavigating complex patients using an innovative tool: the MTM Spider WebJ Am Pharm Assoc (2003)201353553053824030131
- ismp.org [homepage on the Internet]ISMP High-alert medications. Institute for Safe Medication Practices; 2015 [cited October 10, 2014] Available from: http://www.ismp.org/Tools/highAlertMedicationLists.aspAccessed June 27, 2015
- KopeckyCUse of noninsulin antidiabetic medications in hospitalized patientsCrit Care Nurs Clin North Am2013251395323410645
- ClassenDCJaserLBudnitzDSAdverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillanceJt Comm J Qual Patient Saf2010361122120112660
- GellerAIShehabNLovegroveMCNational estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizationsJAMA Intern Med2014174567868624615164
- MilliganFJKrentzAJSinclairAJDiabetes medication patient safety incident reports to the National Reporting and Learning Service: the care home settingDiabet Med201128121537154021883430
- MitchellVDPorterKBeattySJAdministration technique and storage of disposable insulin pens reported by patients with diabetesDiabetes Educ201238565165822722612
- CohenMRPharmacists’ role in ensuring safe and effective hospital use of insulinAm J Health Syst Pharm20106716 Suppl 8S17S2120689148
- Joint Commission International [homepage on the Internet]JCI-Accredited Organizations Available from: http://www.jointcommissioninternational.org/about-jci/jci-accredited-organizations/?c=China&a=Academic%20Medical%20Center%20Hospital%20ProgramAccessed July 10, 2015
- Chinese Diabetes Society. [homepage on the Internet] Available from: http://www.diab.net.cn/guideline.jsp
- LiWZhuLLZhouQSafe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical interventionTher Clin Risk Manag20139657223459439
- ZhuLLZhouQIntervention for improving the appropriateness of physician orders for oral medications in geriatric VIP patients during the journey to JCI accreditationTher Clin Risk Manag2013927327523761971
- TornioANiemiMNeuvonenPJBackmanJTDrug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implicationsTrends Pharmacol Sci201233631232222475684
- NiemiMBackmanJTNeuvonenMLaitilaJNeuvonenPJKivistöKTEffects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepirideClin Pharmacol Ther200169419420011309547
- ShobhaJCMuppidiMRInteraction between voriconazole and glimepirideJ Postgrad Med2010561444520393255
- SchellemanHBilkerWBBrensingerCMWanFHennessySAnti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburideClin Pharmacol Ther201088221422220592722
- ParkJYKimKAParkPWParkCWShinJGEffect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazideClin Pharmacol Ther200374433434014534520
- XuHWilliamsKMLiauwWSMurrayMDayROMcLachlanAJEffects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazideBr J Pharmacol200815371579158618204476
- FichtenbaumCJGerberJGInteractions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionClin Pharmacokinet200241141195121112405866
- BaerlocherMOAschMMyersAFive things to know about… metformin and intravenous contrastCMAJ20131851E7823048079
- NiemiMNeuvonenMJuntti-PatinenLBackmanJTNeuvonenPJEffect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinideClin Pharmacol Ther2003741253112844132
- NiemiMNeuvonenPJKivistöKTThe cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinideClin Pharmacol Ther2001701586511452245
- KajosaariLINiemiMNeuvonenMLaitilaJNeuvonenPJBackmanJTCyclosporine markedly raises the plasma concentrations of repaglinideClin Pharmacol Ther200578438839916198658
- HonkalammiJNiemiMNeuvonenPJBackmanJTDose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil dosesDrug Metab Dispos201139101977198621778352
- KajosaariLIBackmanJTNeuvonenMLaitilaJNeuvonenPJLack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideBr J Clin Pharmacol200458439039615373931
- NiemiMBackmanJTJuntti-PatinenLNeuvonenMNeuvonenPJCoadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinideBr J Clin Pharmacol200560220821716042675
- AquilanteCLKosmiskiLABourneDWImpact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazoneBr J Clin Pharmacol201375121722622625877
- ChenYZhuLLZhouQEffects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patientsTher Clin Risk Manag20141043744824966681
- Chinese Diabetes Society. [homepage on the Internet] Available from: http://diab.net.cn/uploadfile/zhusheguideline.pdf
- De ConinckCFridAGasparRResults and analysis of the 2008–2009 Insulin Injection Technique Questionnaire surveyJ Diabetes20102316817920923482
- JiJLouQInsulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010Curr Med Res Opin20143061087109324552616